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LLC-PI& celIs, a kidney-derived cell line grown in defined medium, possess a vasopressin-sensitive 
adenylate cyclase. Somatostatin was able to inhibit the vasopressin-induced increase in adenylate cyclase 
activity, without affecting the basal enzyme activity. This inhibition was competitive. No effect of 
somatostatin could be detected on [3H]vasopressin bi ding suggesting an interaction of somatostatin with 
the vasopressin-sensitive system distal to the hormone-receptor interaction. At variance with 
N6-L-2-phenylisopropyladenosine (PIA), CTP did not potentiate the inhibition by somatostatin. The 
inhibition of the vasopressin stimulation by somatostatin and that by PIA were additive. Changing the 
composition of the cell growth medium increased the number of vasopressin receptors per cell. Cells with 
a high number of vasopressin receptors were less sensitive to inhibition by somatostatin. Such results 
suggested that somatostatin and vasopressin receptors and/or the inhibitory (Ni) and stimulatory (Ns) 
regulatory transducing components are regulated by different mechanisms. 
Somatostaiin Vasopressin Cell culture 
1. INTRODUCTION 
Somatostatin has been reported to exert a wide 
variety of physiological actions. Among these 
effects, several transport processes have been re- 
ported to be inhibited by somatostatin [l-3]. In 
addition somatostatin has been found to have a 
physiologic~ action only on those tissues which 
contain somatostatin (4,5]. Despite the antago- 
nizing effect of somatostatin on antidiuretic hor- 
mone action on’ the mammalian kidney [6,7], 
somatostatin has not been detected in this tissue. 
This is likely to be due to the high cellular hetero- 
geneity within the kidney. Authors in [S] detected 
immunoreactive somatostatin in the toad urinary 
bladder, a useful established model for studying 
the mechanisms of antidiuretic hormone action in 
vivo. Addition of exogenous omatostatin inhibited 
reversibly the vasopressin-stimulated osmotic water 
flow without affecting the increase in the short- 
Defined medium Adenyiate cyclase 
circuit current elicited by vasopressin. However, 
although the results suggest a direct effect of 
somatostatin on adenylate cyclase activity, this has 
not been formally proven. 
The cell culture technique has also been exten- 
sively proven to be a valid tool for studying some 
aspects of renal functions 19-121. Using the LLC- 
PKKIL cell line, derived from the kidney, we demon- 
strated a somatostatin-induced inhibition of the 
increase in adenylate cyclase elicited by vaso- 
pressin. 
2. METHODS 
2. I. Adeny~ate cycfuse assay 
The incubation medium was composed of 50 mM 
Tris-HCl (pH 7.4), 1OOpM [LU-~‘P]ATP (0.5,&Z’ 
assay), 5 mM MgClz, 100 pM cyclic 13H]AMP 
(10 000 cpm/assay), 5 units/ml adenosine deamin- 
ase, 50pM papaverine, 120 mM NaCl, 0.5 mg/ml 
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creatine kinase, 2.5 mglml creatine phosphate and 
0.3-0.5 mg/ml particulate enzyme (final volume 
50-100~1). Incubation time was 20min at 30°C. 
The reaction was stopped as in [19] and cyclic 
[32P]AMP searated according to [14]. Sources of 
all materials were as in 1151. Somatostatin was 
from Peninsula. 
2.2, Cell culture 
LLC-P&L cells were a generous gift from Dr 
J.S. Handler (NIH, Bethesda). They were grown 
as in 1161 except for the following: (i) penicillin and 
streptomycin concentrations were half those re- 
ported, (ii) the splitting ratio was 1 : 3, (iii) the 
trypsinisation procedure was stopped by means of 
soybean trypsin inhibitor and (iv) the cells were 
used 2 weeks after seeding. The minimum cell 
culture medium was that of [17]. When cells were 
induced for an increased vasopressin receptor 
number, an enriched medium was used. Its com- 
position will be described in another paper (in 
preparation). 
2.3. Membrane preparation 
Petri dishes were washed 3 times with lOm1 
Ca2*- and MgZf -free phosphate-buffered saline. 
The cells were then disrupted with a tight-fitting 
Dounce homogenizer (15 strokes) in 5 mM Tris- 
HC1 (pH 7.4) and 1 mM EDTA. The homogenate 
from one Petri dish was diluted to 10 ml and spun 
at 10000 x g for 10min. This procedure was 
repeated once and the final pellet used as a source 
of enzyme immediately after enzyme preparation. 
Proteins were determined as in [IS]. 
RESULTS AND DISCUSSION 
Somatostatin induced a dose-dependent inhibi- 
tion of vasopressin-sensitive adenylate cyclase from 
LLC-P&L cells (fig.1). The relative magnitude of 
inhibition increased as the (8-lysine) vasopressin 
(LVP) concentration was lowered. In addition the 
threshold dose of somatostatin eliciting inhibition 
was lower at low LVP concentrations than at 
higher ones. No effect of somatostatin could be 
detected on basal adenylate cyclase activity. The 
plot of the data according to Eadie showed that 
somatostatin behaved as a competitive inhibitor of 
the increase in activity due to vasopressin. As the 
somatostatin concentration increased, the apparent 
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Fig. 1. Inhibition of vasopressin-stimulated adenylate 
cyclase as a function of somatostatin concentration. 
(Upper) Adenylate cyclase activity was measured at dif- 
ferent LVP concentrations as a function of the somato- 
statin (SRIF) concentration. Cells grown in enriched 
medium were used for enzyme preparations to increase 
the vasopressin response. The incubation time was 
20min at 30°C. (0, no LVP; A, 0.2nM LVP; IJ, I nM 
LVP; A, 5 nM LVP; 0.25 nM LVP and D, 20$~I LVP). 
(Lower) Data presented in the upper panel were plotted 
according to Eadie. The increase in adenylate cyclase (V) 
due to LVP was plotted as a function of V/LVP con- 
centration at various somatostatin concentrations (0, 
no SRIF; i , l.l~M SRIF; 0,3.3pM SRIF; A, lO#M 
SRIF and a, 30 /IM SRIF). 
affinity for adenylate cyclase activation by LVP 
was decreased. Using rn~irn~ LVP concentra- 
tions, similar maximum velocities were obtained. 
The data presented in fig.2 show that the inhibi- 
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Fig.2. Eadie plot of vasopressin-dependent adenylate 
activity: effects of somatostatin and GTP. Cells grown 
in modified culture were used. Adenylate cyclase activity 
was measured as a function of the LVP concentration 
with (0) or without (0) 10pM somatostatin (SRIF). The 
data were plotted as in fig.1, lower panel. The basal 
adenylate cyclase activities in the absence of GTP were 
equal to 34 (no SRIF) and 33 (+SRIF) pmol CAMP/S min 
per mg protein and to 46 (no SRIF) and 43 (+SRIF) 
pmol CAMP/S min per mg protein in the presence of 
0.25/rM GTP. (Left) With (and without) somatostatin 
the Kapp for enzyme activation and maximum velocities 
were respectively equal to 1.60 nM and (0.89 nM), 344 
and (359) pmol CAMP/S min per mg protein. (Right) 
Maximum velocities and KBpp for enzyme activation 
were equal to 503 pmol CAMP/S min per mg protein 
and 0.94nM (without somatostatin) and 464pmol 
CAMP/S min per mg protein and 1.80 nM (with 
somatostatin). 
tory effects of somatostatin on vasopressin stimu- 
lation were neither potentiated nor abolished upon 
addition of 0.25 or 10,~M (not shown) GTP to the 
adenylate cyclase assay medium. Provided high 
enough LVP concentrations were used, the same 
maximum velocity was reached. In addition GTP 
did not affect the affinity of the adenylate cyclase 
system for somatostatin since the ratio of the ap- 
parent affinities for LVP measured with and with- 
out somatostatin were identical irrespective of the 
presence of GTP, These data confirmed the com- 
petitive action of somatostatin on the LVP-induced 
response. 
Such a competition could be explained by a 
direct interaction of somatostatin with the LVP 
binding to the antidiureti~ hormone receptor. 
Therefore a Scatchard analysis of [3H] LVP binding 
data was undertaken (not shown). The & values 
(&SD) for hormonal binding were found to be 
equal to 5.6k2.3, 8.9k3.1 and 7.6+ 1.7nM in 
the control condition or with 1OpM GTP or 10~M 
somatostatin, respectively. For the same experimen- 
tal conditions; the respective maximum binding 
capacities were found to be equal to 253 + 17,. 
320 * 20 and 252 rt 10 fmol receptor/mg protein 
(&SD). From these data it was therefore concluded 
that somatostatin was not competing for 13HfLVP 
binding. Both hormones must therefore interact 
with each other at a step beyond their receptors to 
antagonize the LVP-induced adenylate cyclase 
activation. 
N6-L-2-Phenylisopropyladenosine (PIA) is able 
to lower basal and to a greater extent hormonally 
stimulated adenylate cyclase activities (in prepara- 
tion). However PIA inhibition of the adenylate 
cyclase activity was potentiated by GTP in contrast 
to that with somatostatin described above. In addi- 
tion, PIA inhibition could not be relieved by in- 
Table 1 
Interactions between PIA and somatostatin on the increase in adenylate cyclase activity due to LVP 
PIA 
OrM) 
GTP 
CuM) 
Increase in activity % decrease in Yo of response to 1fcM LVP 
due to 1 nM LVP activity due to 10 nM 
(pmol/5 min per mg somatostatin -SRIF +SRIF 
protein) 
0 0 110 25 43 33 
30 0 94 31 40 30 
0 10 118 37 46 32 
30 10 71 37 41 71 
The basal adenylate cyclase activities were equal to: 70 (0 PIA, 0 GTP); 181 (+ PIA, 0 GTP); 117 (0 PIA, + GTP) and 
231 (+ PIA, + GTP) pmol CAMP/S min per mg protein. Results are means of triplicate determinations 
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Table 2 
Effects of vasopressin receptor density on the relative inhibition by somatostatin 
April 1984 
Cells 
grown 
GTP Changes in activity (pmol CAMP/S min 
(LOfiM) per mg protein) due to 
% inhibition due to 
somatostatin (B/A) 
2nM LVP 
(A) 
2nM LVP + 5pM 
somatostatin 
(B) 
Minimum medium 0 10.1 3.7 63 
Minimum medium + 15.7 5.9 62 
Modified medium 0 117 96 18 
Modified medium + 150 121 19 
The basal adenylate cyclase activities measured with and without GTP were respectively equal to 44 and 87pmoI 
CAMP/S min per mg protein for cells grown in the minimum medium and to 42 and 83 pmol CAMP/S min per mg 
protein for cells grown in the modified medium. Data are means of triplicate values which agreed within k2@70 
creasing the dose of LVP. Since the modalities of 
inhibition by PIA and somatostatin appeared to be 
different it was of interest to see whether they 
share a common mechanism of action (table 1). 
PIA inhibited the adenylate cyclase response to a 
greater extent when GTP was present. Somatosta- 
tin, irrespective of the presence of PIA and/or 
GTP, was able to induce additional inhibition of 
enzyme activity. The relative magnitude of this in- 
hibition was independent of the degree of inhibi- 
tion already achieved with PIA. Therefore the ap- 
parent affinity of somatostatin for vasopressin 
inhibition of adenylate cyclase was not affected by 
the presence of PIA (PIA per se did not change the 
apparent affinity of LVP for the enzyme activa- 
tion) (not shown). 
The LLC-PKI cells, i.e., the parent cell line of 
the cells used here, are grown in the presence of 10% 
foetal bovine serum. These cells have more than 
50-times the vasopressin receptor number com- 
pared to LLC-PKrr cells and their vasopressin- 
sensitive adenylate cyclase cannot be altered upon 
somatostatin addition (not shown). By making 
appropriate modifications of the cell culture 
medium, it was possible to increase by lo-20-fold 
the receptor number in LLC-P&J_ cells. The 
results listed in table 2 show that these cells were 
still responsive to somatostatin. The absolute 
decrease in activity due to somatostatin was larger 
when the enzyme response to vasopressin was the 
highest. However, the relative inhibition was less. 
Again the addition of GTP to the adenylate cyclase 
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assay medium did not alter the inhibitory property 
of somatostatin. Such data, taken together with 
those obtained on LLC-PI<1 cells may suggest he 
following: 
(9 
(ii) 
(iii) 
The-addition of serum did not allow the exis- 
tence or expression of a somatostatin receptor; 
Vasopressin and somatostatin receptors have 
distinct regulatory pathways and can be ex- 
pressed independently; 
The transduction mechanism of the somato- 
statin receptor becomes a limiting factor for 
regulating high levels of stimulation induced 
by vasopressin. 
4. CONCLUSIONS 
Somatostatin has been shown to be effective in in- 
hibiting the hormone stimulation in many [3,19,20] 
but not all tissues [21]. To our knowledge, this is 
the first demonstration of an inhibitory effect of 
somatostatin on the anti~uretic hormone-stimu- 
lated adenlyate cyclase. The stimulated state of 
adenylate cyclase appeared to be a prerequisite for 
demonstrating inhibition by somatostatin (221. 
However, all stimulated states of adenylate cyclase 
are not inhibitable by somatostatin as exemplified 
in the case of enzyme activation by PIA (when no 
GTP was added). In contrast inhibition by PIA 
and that by somatostatin were additive (in the 
presence of GTP). 
The adenylate cyclase system is a multicompo- 
nent regulatory complex. It is composed of a 
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receptor (R), a catalytic unit (C) and a transduc- 
tion mechanism (N). At present two distinct N 
units have been described. N, stimulates C and Ni 
mediates the inhibition of C. The LVP-mediated 
response is supposed to regulate adenylate cyclase 
activity through N,, while inhibitory effects of PIA 
are supposed to be mediated through the Ni unit. 
Stimulations of C by LVP and PIA are additive. 
Similarly inhibitions of the LVP response by PIA 
aad somatostatin are also additive (in the presence 
of GTP). Both somatostatin and PIA can inhibit 
the LVP response but had no effect on PIA stimu- 
lation. This would exclude the possibility that 
somatostatin has a direct effect on C. However it 
has been shown to be able to inhibit the forskolin- 
and cholera toxin-activated state of C [22]. Alter- 
natively somatostatin might act on Nr coupled to 
C. This would imply that the mechanisms of en- 
zyme activation by PIA and by LVP are different 
since they do not exhibit the same sensitivity to 
PIA inhibition. 
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